What is the mechanism of action of Val-Cit-PAB-MMAE?

Val-Cit-PAB-MMAE delivers MMAE to cells by linking it to antibodies. Once internalized by target cells, the linker is cleaved, releasing MMAE to disrupt microtubule assembly, leading to cell death.

What applications are best suited for using Val-Cit-PAB-MMAE?

Val-Cit-PAB-MMAE is best suited for use in preclinical studies of antibody-drug conjugates (ADCs) targeting various cancers, including breast, lung, and lymphoma models.

What are the benefits of using Val-Cit-PAB as a linker for MMAE in drug conjugates?

Val-Cit-PAB provides a stable, cleavable linker that remains intact in the bloodstream but is efficiently cleaved in the lysosome, ensuring precise release of MMAE at the target site within cancer cells.

Is Val-Cit-PAB-MMAE compatible with different antibodies, and what factors affect conjugation efficiency?

Val-Cit-PAB-MMAE is compatible with a variety of antibodies; however, factors such as antibody isotype, conjugation site, and linker chemistry can affect conjugation efficiency and overall ADC stability.

How does Val-Cit-PAB-MMAE specifically target cancer cells?

Val-Cit-PAB-MMAE is conjugated to monoclonal antibodies that bind to specific antigens on cancer cells, delivering the cytotoxic MMAE (monomethyl auristatin E) directly to the targeted tumor cells.

Val-Cit-PAB-MMAE (CAT#: ADC-S-079)

Linker-Toxin SET, this set is made by MMAE conjugated to the lysosomally cleavable Val-Cit-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.

Product Information

CAS NO
644981-35-1

Description
Linker-Toxin SET, this set is made by MMAE conjugated to the lysosomally cleavable Val-Cit-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.

Molecular Weight
1123.43

Purity
95%

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-S-079. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

The Val-Cit-PAB-MMAE product from Creative Biolabs has been instrumental in my antibody-drug conjugate research. The stability and high efficacy of the linker and drug conjugate exceeded expectations, resulting in consistently reliable experimental results.

Excellent

Creative Biolabs' Val-Cit-PAB-MMAE is a well-formulated compound for ADC studies. It offers excellent drug release and stability, significantly improving my research output in targeted cancer therapies.

Excellent

Using Val-Cit-PAB-MMAE in our lab yielded impressive results. The controlled drug release mechanism functioned perfectly, ensuring targeted cytotoxicity in our cell assays.

Excellent

The Val-Cit-PAB-MMAE linker from Creative Biolabs has become a key component in our ADC experiments. The product's purity and functionality ensured high efficiency in our tests, delivering potent cytotoxicity to target cells with minimal off-target effects.

Excellent

Our team has found Creative Biolabs' Val-Cit-PAB-MMAE to be an excellent choice for ADC research. Its stability and effectiveness in drug delivery have proven invaluable in developing our targeted therapies. A reliable and efficient product.

Q: 1: What is the mechanism of action of Val-Cit-PAB-MMAE?
A: Val-Cit-PAB-MMAE delivers MMAE to cells by linking it to antibodies. Once internalized by target cells, the linker is cleaved, releasing MMAE to disrupt microtubule assembly, leading to cell death.
Q: 2: What applications are best suited for using Val-Cit-PAB-MMAE?
A: Val-Cit-PAB-MMAE is best suited for use in preclinical studies of antibody-drug conjugates (ADCs) targeting various cancers, including breast, lung, and lymphoma models.
Q: 3: What are the benefits of using Val-Cit-PAB as a linker for MMAE in drug conjugates?
A: Val-Cit-PAB provides a stable, cleavable linker that remains intact in the bloodstream but is efficiently cleaved in the lysosome, ensuring precise release of MMAE at the target site within cancer cells.
Q: 4: Is Val-Cit-PAB-MMAE compatible with different antibodies, and what factors affect conjugation efficiency?
A: Val-Cit-PAB-MMAE is compatible with a variety of antibodies; however, factors such as antibody isotype, conjugation site, and linker chemistry can affect conjugation efficiency and overall ADC stability.
Q: 5: How does Val-Cit-PAB-MMAE specifically target cancer cells?
A: Val-Cit-PAB-MMAE is conjugated to monoclonal antibodies that bind to specific antigens on cancer cells, delivering the cytotoxic MMAE (monomethyl auristatin E) directly to the targeted tumor cells.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

For Research Use Only. NOT FOR CLINICAL USE.

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.